Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Primary Myelofibrosis 13Myeloproliferative Disorders 10Polycythemia Vera 9Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 6Graft vs Host Disease 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Thrombocythemia, Essential 4Hematologic Neoplasms 4Breast Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Other Cancer × ruxolitinib × Clear all
NCT03674047 2025-11-10

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Massachusetts General Hospital

Phase 2 Active not recruiting
50 enrolled

Other Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡